Saturday - February 14, 2026
Positive and Clinically Meaningful Results From the Phase III KALOS and LOGOS Trials for BREZTRI in Patients With Uncontrolled Asthma Published in The Lancet Respiratory Medicine
February 14, 2026
WILMINGTON, Delaware, Feb. 14 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine

Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine (https://www.thelancet.com/journals/lanres/artic . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products